Relevant bibliographies by topics / Psilocyn

Academic literature on the topic 'Psilocyn'

Author: Grafiati
Published: 10 December 2022
Last updated: 28 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Psilocyn.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Psilocyn"

1

McKernan, Kevin, Liam Kane, Yvonne Helbert, Lei Zhang, Nathan Houde, and Stephen McLaughlin. "A whole genome atlas of 81 Psilocybe genomes as a resource for psilocybin production." F1000Research 10 (December 17, 2021): 961. http://dx.doi.org/10.12688/f1000research.55301.2.

Full text
Abstract:
The Psilocybe genus is well known for the synthesis of valuable psychoactive compounds such as Psilocybin, Psilocin, Baeocystin and Aeruginascin. The ubiquity of Psilocybin synthesis in Psilocybe has been attributed to a horizontal gene transfer mechanism of a ~20Kb gene cluster. A recently published highly contiguous reference genome derived from long read single molecule sequencing has underscored interesting variation in this Psilocybin synthesis gene cluster. This reference genome has also enabled the shotgun sequencing of spores from many Psilocybe strains to better catalog the genomic diversity in the Psilocybin synthesis pathway. Here we present the de novo assembly of 81 Psilocybe genomes compared to the P.envy reference genome. Surprisingly, the genomes of Psilocybe galindoi, Psilocybe tampanensis and Psilocybe azurescens lack sequence coverage over the previously described Psilocybin synthesis pathway but do demonstrate amino acid sequence homology to a less contiguous gene cluster and may illuminate the previously proposed evolution of psilocybin synthesis.
APA, Harvard, Vancouver, ISO, and other styles
2

McKernan, Kevin, Liam Kane, Yvonne Helbert, Lei Zhang, Nathan Houde, and Stephen McLaughlin. "A whole genome atlas of 81 Psilocybe genomes as a resource for psilocybin production." F1000Research 10 (September 23, 2021): 961. http://dx.doi.org/10.12688/f1000research.55301.1.

Full text
Abstract:
The Psilocybe genus is well known for the synthesis of valuable psychoactive compounds such as Psilocybin, Psilocin, Baeocystin and Aeruginascin. The ubiquity of Psilocybin synthesis in Psilocybe has been attributed to a horizontal gene transfer mechanism of a ~20Kb gene cassette. A recently published highly contiguous reference genome derived from long read single molecule sequencing has underscored interesting variation in this Psilocybin synthesis gene cassette. This reference genome has also enabled the shotgun sequencing of spores from many Psilocybe strains to better catalog the genomic diversity in the Psilocybin synthesis pathway. Here we present the de novo assembly of genomes of 81 Psilocybe genomes compared to the P.envy reference genome. Surprisingly, the genomes of Psilocybe galindoi, Psilocybe tampanensis and Psilocybe azurescens lack sequence coverage over the previously described Psilocybin synthesis pathway but do demonstrate amino acid sequence homology to an alternative pathway and may illuminate previously proposed convergent evolution of Psilocybin synthesis.
APA, Harvard, Vancouver, ISO, and other styles
3

Wieczorek, Marek. "The effect of particular active substances of hallucinogenic mushrooms." Folia Biologica et Oecologica 10 (November 30, 2014): 40–48. http://dx.doi.org/10.2478/fobio-2014-0014.

Full text
Abstract:
Magic mushrooms have accompanied man for thousands of years. Formerly they were used for religious and culture purposes. Those fungi belong mainly to the genera Conocybe, Copelandia, Panaeolus, Psilocybe and Stropharia. A number of these fungal species produce substances, like psilocybin, psilocin, ibotenic acid or muscimol. Because of their chemical similarity to naturally occurring neurotransmitters like serotonin and GABA these substances, after ingestion, affect brain neurochemistry and by this induce hallucinations. This mini review presents the influence of psilocybin, psilocin, ibotenic acid and muscimol on the nervous system. Also the effects of the above mentioned substances on emotion and mental health of people are discussed.
APA, Harvard, Vancouver, ISO, and other styles
4

Law, Francis, Grace Poon, Y. C. Chui, and Shao-Xiong He. "14C-Psilocin tissue distribution in pregnant rats after intravenous administration." Functional Foods in Health and Disease 4, no. 6 (July 27, 2014): 232. http://dx.doi.org/10.31989/ffhd.v4i6.9.

Full text
Abstract:
Background: Many species of hallucinogenic mushrooms have been found in the genus Psilocybe. The main psychoactive chemicals of Psilocybe mushrooms are psilocin and its phosphoryloxy derivative, psilocybin. In addition to its psychedelic effects, psilocybin is an effective agent to lift the mood of depressed patients with terminal cancers.Objective: To study the dispositional kinetics of 14C-psilocin in pregnant rats after intravenous injection, to calculate tissue dose surrogates i.e., tissue 14C concentration and area under the concentration-time curve using the experimental data, to quantify trans-placental passage of psilocin and/or its metabolites, and to identify new psilocin metabolite(s) in rat urine.Methods: A group of 15 pregnant Wistar rats weighing between 0.30-0.36 kg was used in the study. Each rat was given a single dose of 7.5 mg/kg 14C-psilocini.v. Three rats were randomly selected and sacrificed at 0.5, 1.0, 2.0, 4.0, and 8.0 hr post-dosing. The maternal and fetal tissues were quickly removed and the radioactivity in these tissues determined by liquid scintillation counting.In a separate study, urine samples were collected from 6 male Wistar rats after administering 15 mg/kg of unlabeled psilocin i.p. The urine samples were collected and extracted by chloroform-methanol (9:1 v/v) and analyzed using a gas chromatograph/mass spectrometer.Results: 14C-Psilocin crossed the placental barrier of pregnant rats readily after i.v. administration; maternal tissue 14C concentrations were found to be much higher than those in fetal tissues. The areas under the curve for maternal tissues also were much higher than the fetal tissues. In general, maternal tissues could be divided into the fast eliminating organ group, which included the brain (elimination half-life <13 hr) and the slow eliminating organ group, which included all fetal tissues (elimination half-life >13 hr). A new psilocin metabolite tentatively identified as dihydroxyindoleacetic acid was found in the urine.Conclusion: Our study showed that psilocin readily crossed the placental and blood-brain barriers of pregnant rats. Because psilocin was eliminated slowly from the fetal tissues of rats, human consumption of magic mushrooms should be avoided during pregnancy. Key words: magic mushrooms, psilocin, placental barrier, pregnant rats
APA, Harvard, Vancouver, ISO, and other styles
5

Kuhn, Antonia, and Matthias F. Melzig. "Psilocybe mexicana R. Heim – Mexikanischer Kahlkopf." Zeitschrift für Phytotherapie 43, no. 02 (April 2022): 89–94. http://dx.doi.org/10.1055/a-1540-9907.

Full text
Abstract:
Psilocybe mexicana R. Heim ist ein Pilz mit langer ethnopharmakologischer Tradition, der als wirkungsbestimmende Inhaltsstoffe Psilocybin und Psilocin enthält. Die psychostimulierende, halluzinogene Wirkung wurde bisher vor allem in traditionellen Zeremonien der indigenen Bevölkerung Mittel- und Südamerikas genutzt. Die Eignung als Therapeutikum für verschiedene psychische Krankheiten, wie der Depression, soll in aktuellen klinischen Studien untersucht werden. Noch ist die Studienlage nicht ausreichend und sind zugrundeliegende Mechanismen nicht abschließend geklärt.
APA, Harvard, Vancouver, ISO, and other styles
6

Kuhn, Antonia, and Matthias F. Melzig. "Psilocybe mexicana R. Heim – Mexikanischer Kahlkopf." Zeitschrift für Phytotherapie 43, no. 02 (April 2022): 89–94. http://dx.doi.org/10.1055/a-1540-9907.

Full text
Abstract:
Psilocybe mexicana R. Heim ist ein Pilz mit langer ethnopharmakologischer Tradition, der als wirkungsbestimmende Inhaltsstoffe Psilocybin und Psilocin enthält. Die psychostimulierende, halluzinogene Wirkung wurde bisher vor allem in traditionellen Zeremonien der indigenen Bevölkerung Mittel- und Südamerikas genutzt. Die Eignung als Therapeutikum für verschiedene psychische Krankheiten, wie der Depression, soll in aktuellen klinischen Studien untersucht werden. Noch ist die Studienlage nicht ausreichend und sind zugrundeliegende Mechanismen nicht abschließend geklärt.
APA, Harvard, Vancouver, ISO, and other styles
7

Brenneisen, Rudolf, and Stefan Borner. "The Occurrence of Tryptamine Derivatives in Psilocybe semilanceata." Zeitschrift für Naturforschung C 43, no. 7-8 (August 1, 1988): 511–14. http://dx.doi.org/10.1515/znc-1988-7-806.

Full text
Abstract:
The content of tryptamine derivatives in Psilocybe semilanceata, a popular hallucinogenic mushroom, was measured by high-performance liquid chromatography. Most of the 52 samples have been collected at several localities in Switzerland during a 1-5 year period. The content of psilocybin and baeocystin varied in the range of 0.21-2.02% and 0.05-0.77%, respectively, whereas only traces of psilocin were present. The variability of the alkaloid level depending on origin, year of collection, size and part of mushrooms is discussed.
APA, Harvard, Vancouver, ISO, and other styles
8

Polo-Castellano, Curro, José Á. Álvarez, Miguel Palma, Gerardo F. Barbero, Jesús Ayuso, and Marta Ferreiro-González. "Optimization through a Box–Behnken Experimental Design of the Microwave-Assisted Extraction of the Psychoactive Compounds in Hallucinogenic Fungi (Psylocibe cubensis)." Journal of Fungi 8, no. 6 (June 2, 2022): 598. http://dx.doi.org/10.3390/jof8060598.

Full text
Abstract:
Hallucinogenic fungi, mainly those from the Psilocybe genus, are being increasingly consumed even though there is no control on their culture conditions. Due to the therapeutic potential as antidepressants and anxiolytics of the alkaloids that they produce (psilocin and psilocybin), some form of control on their production would be highly recommended. Prior to identifying their optimal culture condition, a methodology that allows their study is required. Microwave-assisted extraction method (MAE) is a technique that has proven its efficiency to extract different compounds from solid matrices. For this reason, this study intends to optimize a MAE method to extract the alkaloids found in Psylocibe cubensis. A surface-response Box–Behnken design has been employed to optimize such extraction method and significantly reduce time and other resources in the extraction process. Based on the Box–Behnken design, 50 °C temperature, 60% methanol as extraction solvent, 0.6 g:10 mL sample mass:solvent ratio and 5 min extraction time, were established as optimal conditions. These mild conditions, combined with a rapid and efficient UHPLC analysis result in a practical and economical methodology for the extraction of psilocin and psilocybin from Psylocibe cubensis.
APA, Harvard, Vancouver, ISO, and other styles
9

Hackl, Benjamin, Hannes Todt, Helmut Kubista, Karlheinz Hilber, and Xaver Koenig. "Psilocybin Therapy of Psychiatric Disorders Is Not Hampered by hERG Potassium Channel–Mediated Cardiotoxicity." International Journal of Neuropsychopharmacology 25, no. 4 (December 6, 2021): 280–82. http://dx.doi.org/10.1093/ijnp/pyab085.

Full text
Abstract:
Abstract Psilocybin, a hallucinogen contained in “magic” mushrooms, holds great promise for the treatment of various psychiatric disorders, and early clinical trials are encouraging. Adverse cardiac events after intake of high doses of psilocybin and a trial reporting QT interval prolongation in the electrocardiogram attributed to the drug’s main metabolite, psilocin, gave rise to safety concerns. Here we show that clinical concentrations of psilocin do not cause significant human ether-a-go-go-related gene (hERG) potassium channel inhibition, a major risk factor for adverse cardiac events. We conclude that hERG channel blockage by psilocin is not liable for psilocybin- associated cardiotoxic effects.
APA, Harvard, Vancouver, ISO, and other styles
10

Lewis, Candace R., Katrin H. Preller, B. Blair Braden, Cory Riecken, and Franz X. Vollenweider. "Rostral Anterior Cingulate Thickness Predicts the Emotional Psilocybin Experience." Biomedicines 8, no. 2 (February 18, 2020): 34. http://dx.doi.org/10.3390/biomedicines8020034.

Full text
Abstract:
Psilocybin is the psychoactive compound of mushrooms in the psilocybe species. Psilocybin directly affects a number of serotonin receptors, with highest affinity for the serotonin 2A receptor (5HT-2Ar). Generally, the effects of psilocybin, and its active metabolite psilocin, are well established and include a range of cognitive, emotional, and perceptual perturbations. Despite the generality of these effects, there is a high degree of inter-individual variability in subjective psilocybin experiences that are not well understood. Others have shown brain morphology metrics derived from magnetic resonance imaging (MRI) can predict individual drug response. Due to high expression of serotonin 2A receptors (5HT-2Ar) in the cingulate cortex, and its prior associations with psilocybin, we investigate if cortical thickness of this structure predicts the psilocybin experience in healthy adults. We hypothesized that greater cingulate thickness would predict higher subjective ratings in sub-scales of the Five-Dimensional Altered State of Consciousness (5D-ASC) with high emotionality in healthy participants (n = 55) who received oral psilocybin (either low dose: 0.160 mg/kg or high dose: 0.215 mg/kg). After controlling for sex, age, and using false discovery rate (FDR) correction, we found the rostral anterior cingulate predicted all four emotional sub-scales, whereas the caudal and posterior cingulate did not. How classic psychedelic compounds induce such large inter-individual variability in subjective states has been a long-standing question in serotonergic research. These results extend the traditional set and setting hypothesis of the psychedelic experience to include brain structure metrics.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Psilocyn"

1

Shaba, Reham. "Development of an improved psilocybin synthesis." Thesis, Uppsala universitet, Uppsala universitet Innovation (UU Innovation), 2020. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-420295.

Full text
Abstract:
Psilocybin is a hallucinogenic compound found in fungi and is currently evaluated inclinical trials for treatment of depression, anxiety and addiction. Psilocybin is aprodrug of the pharmacologically active metabolite, psilocin. The synthetic route topsilocybin relies on synthesizing psilocin from the starting material, 4-hydroxyindoleand latter converting psilocin into psilocybin by phosphorylation. The synthesis ofpsilocybin has been challenging because of the labile nature of the phosphorylationdibenzyl ester reagent and related intermediates. Several attempts to optimizepsilocybin synthesis have been published but there is still a need for furtherimprovements.The first aim of this project was to synthesize psilocybin using literature methods,while the second aim was to optimize the phosphorylation step with differentreagents and conditions.Initial studies focused on coupling the two-side chain carbon onto position three ofthe indole, this required protection of the hydroxyl group which was achieved byacylation in room temperature. With sufficient amount of dimethylamine solution, theamine addition reaction was investigated and resulted in a pure product. Thefollowing reduction with lithium aluminum hydride provided an unknown side-productinstead of psilocin.The first aim was successfully accomplished, up to psilocin, with pure intermediatesbut low yields. The second aim was not achieved due to lack of time and access tothe laboratory during covid-19 crisis. However, a literature survey of reagents andconditions for phosphorylation was performed which enables continuation of theproject.
APA, Harvard, Vancouver, ISO, and other styles
2

Engström, Natalie. "Lysergsyradietylamid (LSD) och psilocybin vid depression och ångestsjukdom : En litteraturstudie om effekter och biverkningar av LSD- och psilocybin-assisterad psykoterapi." Thesis, Umeå universitet, Farmakologi, 2017. http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-136681.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Gabay, Anthony Stuart. "An investigation of social cognition using psilocybin and MDMA." Thesis, King's College London (University of London), 2017. https://kclpure.kcl.ac.uk/portal/en/theses/an-investigation-of-social-cognition-using-psilocybin-and-mdma(dedc1c2c-5023-4cba-9994-6178214334f3).html.

Full text
Abstract:
Impairments of social function are increasingly thought to be fundamental to the psychopathology of psychiatric disorders. Current treatments are not assessed against these social domains and the effects of medication are poorly understood. Furthermore, the neural mechanisms and psychopharmacology underlying these functions in the healthy population are poorly understood. This thesis addresses this knowledge gap. A meta-analysis of antipsychotic treatment effects on emotion processing in schizophrenia confirms the lack of efficacy of current treatments in treating these social deficits. Following this, the thesis largely focuses on social decision-making, investigating tasks which model trust, cooperation and social norm violations. A meta-analysis of neuroimaging studies investigating the Ultimatum Game (UG) provides robust evidence of regions underlying the processing of social norms. Results are presented from two psychopharmacological studies, utilising serotonergic agonists to investigate their effects on social decision-making and emotion processing. The first study administered psilocybin with an open-label design. This study additionally investigated the efficacy of a src-kinase inhibitor to attenuate any psilocybin effect; this followed a placebo-controlled, double-blind design. The second study investigated 3,4-methylenedioxymethamphetamine (MDMA) with a placebo-controlled, double-blind design. Both MDMA and psilocybin caused a decrease in rejection of unfair offers in the UG. MDMA increased cooperation with trustworthy, but not untrustworthy, partners in an iterated Prisoner’s Dilemma (PD), as well as reducing recognition of negative facial affect. Increased cooperation in the PD was accompanied by increased activation in the superior temporal sulcus, cingulate cortex and insula, during feedback of other player’s decisions. The findings of these studies suggest that serotonergic mechanisms are fundamental to the processing of normative behaviour during interpersonal interactions. Manipulation of this neurotransmitter system produced context-sensitive changes in behaviour. These behavioural alterations were accompanied by changes in activity of brain regions proposed to be involved in the processing and appraisal of other’s intentions and motivations. It is hypothesised that this was largely achieved through activity at the serotonin 2A receptor. These findings provide insight for the development of new treatment mechanisms for disorders of social cognition.
APA, Harvard, Vancouver, ISO, and other styles
4

Keay, Susan M. "Psilocybe semilanceata : hyphal interactions with the roots of grassland flora." Thesis, Queen's University Belfast, 1987. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.317086.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Allgulin, Marcus. "Psilocybin and LSD in the Treatment of Depression and Anxiety." Thesis, Högskolan i Skövde, Institutionen för biovetenskap, 2020. http://urn.kb.se/resolve?urn=urn:nbn:se:his:diva-18843.

Full text
Abstract:
Psychiatry is in a crisis. Mental health disorders are on the rise worldwide and there are currently not enough efficient treatment methods that would meet the patients’ needs. Hence, the societal and economic costs of mental health problems are enormous, as well as the suffering of individuals afflicted by mental health problems. Lysergic acid diethylamide (LSD) and psilocybin are substances that create an altered state of consciousness characterized by altered sensory perception and on some occasions, ego-dissolution, and mystical experiences. In recent studies, LSD and psilocybin have been shown to carry significant therapeutic potential in the treatment of depression and anxiety disorders in conjunction with psychotherapy. The therapeutic effects of LSD and psilocybin have also been shown to persist for between 3-12 months post-treatment. LSD and psilocybin, like other classical hallucinogens, increase serotonin availability, which has been suggested to attenuate symptoms of anxiety and depression. In addition, LSD and psilocybin alter the activity of the default mode network, which has been suggested to be overly active in depressed and anxious patients. This essay is a literature review of the neural mechanisms of LSD and psilocybin, their potential therapeutic effects in the treatment of depressive and anxiety disorders, and how insights about said neural mechanisms may be useful in understanding the possible application of psychedelics in the treatment of depressive and anxiety disorders. In sum, recent studies have provided converging and convincing evidence on therapeutic potential of LSD and psilocybin. Yet, few conclusions on the exact neural mechanisms of how LSD and psilocybin alleviate depressive and anxiety symptoms can be made. Although the future of this research field looks promising, archaic national- and international regulations continue to be a hindrance to research into psychedelic drugs. Yet, due to the psychiatric crisis and the promising results so far, more studies in this field are warranted.
APA, Harvard, Vancouver, ISO, and other styles
6

Stendahl, Isabella. "THE POTENTIAL THERAPEUTIC VALUE OF PSILOCYBIN : In Relation to Depression." Thesis, Högskolan i Skövde, Institutionen för biovetenskap, 2019. http://urn.kb.se/resolve?urn=urn:nbn:se:his:diva-17749.

Full text
Abstract:
Depression is one of the most disabling and prevalent mental disorders, which causes excessive feelings of sadness and despair. Unfortunately, there are a substantial number of patients that do not respond well to conventional interventions and new approaches are therefore needed. Recent studies have revealed that psilocybin can effectively reduce symptoms of depression and anxiety, particularly when combined with psychological support. It has been further suggested that psilocybin can reduce symptoms of alcohol abuse, cluster headaches and obsessive-compulsive disorder (OCD). Results have shown that psilocybin can give long-lasting beneficial changes in mood, behavior, values, and attitudes. Psilocybin enables creative thinking and increases emotional access, which seems suitable for therapeutic implications. Neuroimaging studies have shown that psilocybin alters similar neural networks to those in depressed patients, in particular: the medial prefrontal cortex, posterior cingulate cortex, and the amygdala. The mechanisms behind the clinical improvements are still poorly understood. Using psilocybin for clinical purposes is controversial since it is categorized as a Schedule I substance, although the drug is not physically addictive nor harmful and has low abuse potential. Recent studies have demonstrated that psilocybin has clinical potential and is safe to use in supervised settings.
APA, Harvard, Vancouver, ISO, and other styles
7

Wark, Colin D. "A social and cultural history of the federal prohibition of psilocybin." Diss., Columbia, Mo. : University of Missouri-Columbia, 2007. http://etd.missouri.edu/Summer2007/Dissertation/WarkC-080307-D8335/.

Full text
Abstract:
Thesis (Ph. D.)--University of Missouri-Columbia, 2007.
The entire dissertation/thesis text is included in the research.pdf file; the official abstract appears in the short.pdf file (which also appears in the research.pdf); a non-technical general description, or public abstract, appears in the public.pdf file. Title from title screen of research.pdf file (viewed on December 17, 2007) Vita. Includes bibliographical references.
APA, Harvard, Vancouver, ISO, and other styles
8

Machado, Pedro Miguel Sá. "The frontiers of psychedelic therapy: psilocybin as a new treatment option." Master's thesis, Universidade de Aveiro, 2015. http://hdl.handle.net/10773/14878.

Full text
Abstract:
Mestrado em Biomedicina Farmacêutica
The current work intends to offer a global outlook of the state-of-the-art of clinical research using classic psychedelics, with a special focus on clinical studies using psilocybin, which is the active ingredient in “magic mushrooms”. This thesis approaches the legacy of the research conducted during the 60s, but goes further in depth into the research carried out during the last decade, after several decades of suppression due to the political and legal panorama, evidencing the evolution of clinical studies to comply with currently accepted standards. Psilocybin has been used in clinical studies together with psychological intervention aiming at assessing its safety, dosage and efficacy in alleviating problems such as anxiety, alcohol dependence, tobacco dependence and obsessive-compulsive disorder. The results from clinical research are promising, however, these are small-scale studies with limitations. Therefore, more and larger trials are necessary to better understand the value of this therapy.
O presente trabalho propõe fornecer uma visão geral sobre o estado atual da investigação clínica utilizando psicadélicos clássicos, com especial relevo nos ensaios clínicos com a substância psilocibina que constitui o princípio ativo dos “cogumelos mágicos”. Este trabalho aborda o legado deixado pela pesquisa inicial nos anos 60, mas explora em profundidade a pesquisa conduzida na última década, após várias décadas de supressão devido ao panorama político e legal, evidenciando a evolução dos ensaios clínicos de forma a cumprir os padrões aceites atualmente. A psilocibina tem sido utilizada em ensaios clínicos em conjunto com intervenção psicológica com o intuito de estabelecer a sua segurança, dose e eficácia em aliviar problemas como a ansiedade, dependência do álcool, dependência do tabaco e transtorno obsessivo-compulsivo. Os resultados da pesquisa clínica são promissores, no entanto os ensaios são de pequena escala e apresentam limitações, o que torna necessária a realização de mais e maiores ensaios clínicos para que se possa entender melhor o valor desta terapia.
APA, Harvard, Vancouver, ISO, and other styles
9

Larsson, Anisha Lela. "Mikrodosering av lysergsyradietylamid och psilocybin och dess effekter på psykisk hälsa." Thesis, Uppsala universitet, Institutionen för psykologi, 2018. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-358476.

Full text
Abstract:
Mikrodosering av psykedeliska droger är den senaste trenden som verkar ha fått en stor spridning, främst bland unga människor för att uppnå ökad produktivitet och kreativitet, men även för att uppnå allmän psykisk hälsa. Denna uppsats lägger fokus på lysergsyradietylamid (LSD) och psilocybin (magic mushroom). Mikrodosering innebär att användaren tar en väldigt låg dos av substansen. Dosen ger ingen psykedelisk effekt, d.v.s. inga visuella effekter, inget förändrat medvetandetillstånd,och ingen förändrad tids-eller rumsuppfattning. Deltagare (n=201) besvarade en elektronisk enkät som distribuerades i olika forum med intresse för psykedeliska substanser. I denna deskriptiva sambandsstudie undersöktes motiveringen av att mikrodosera LSD-och psilocybin, samt vilka positiva och negativa effekter mikrodosering av dessa substanser har på den psykiska hälsan.Deltagare uppgav upplevd minskad depression, ångest och stress, men att det inte var den primära anledningen till att de mikrodoserade trots att 62% hade självdiagnostiserat sig med någon form av upplevd ohälsa. De primära motiven med att mikrodosera, som angavs i enkäten, var att förbättra den allmänna hälsan, samt för att nå ökad kreativitet och produktivitet. Trots upplevda negativa bieffekter under mikrodoseringscykeln uppgav majoriteten att de ville fortsätta att mikrodosera. På grund av urvalet är studieresultatet inte generaliserbart och efterföljande undersökningar med hypoteser och frågor är att föreslå.
APA, Harvard, Vancouver, ISO, and other styles
10

Buis, Cécile Sallenave-Namont Claire. "Intoxications par les champignons supérieurs observées au Centre Antipoison d'Angers au cours des années 2000 et 2001." [S.l.] : [s.n.], 2003. http://theses.univ-nantes.fr/thesemed/PHbuis.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Psilocyn"

1

Oss, O. T. Psilocybin: Magic mushroom grower's guide : a handbook for psilocybin enthusiasts. [San Francisco, Calif.?]: Quick American Pub., 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

McKenna, Terence K. True hallucinations: And, the archaic revival. New York: MJF Books, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

True hallucinations: Being an account of the author's extraordinary adventures in the devil's paradise. [San Francisco]: HarperSanFrancisco, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

United Nations. Division of Narcotic Drugs. Recommended methods for testing peyote cactus (mescal buttons)/mescaline and psilocybe mushrooms/psilocybin: Manual for use by national narcotics laboratories. New York: United Nations, 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Psilocybin mushroom legal defenses. Ann Arbor, MI: Swift Run Press, 2013.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Magic mushroom explorer: Psilocybin and the awakening Earth. Rochester, Vermont: Park Street Press, 2015.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Psilocybin mushrooms of the world: An identification guide. Berkeley, Calif: Ten Speed Press, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

One Kind of Knowing: Reports from a Hallucinogen Research Volunteer. [Place of publication not identified]: Maria T. Estevez, 2013.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

The psilocybin solution: The role of sacred mushrooms in the quest for meaning. Rochester, Vt: Park Street Press, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Ralph, Metzner, and Darling Diane, eds. Sacred mushroom of visions: Teonanácatl : a sourcebook on the psilocybin mushroom. Rochester, Vt: Park Street Press, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Psilocyn"

1

Vidal, C., and W. R. Külpmann. "Psilocybin." In Lexikon der Medizinischen Laboratoriumsdiagnostik, 1. Berlin, Heidelberg: Springer Berlin Heidelberg, 2018. http://dx.doi.org/10.1007/978-3-662-49054-9_2589-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Vidal, C., and W. R. Külpmann. "Psilocybin." In Springer Reference Medizin, 2003–4. Berlin, Heidelberg: Springer Berlin Heidelberg, 2019. http://dx.doi.org/10.1007/978-3-662-48986-4_2589.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Mahmood, Zafar Alam. "Bioactive Alkaloids from Fungi: Psilocybin." In Natural Products, 523–52. Berlin, Heidelberg: Springer Berlin Heidelberg, 2013. http://dx.doi.org/10.1007/978-3-642-22144-6_19.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Freye, Enno. "The Mushroom Psilocybin with Psychedelic Properties." In Pharmacology and Abuse of Cocaine, Amphetamines, Ecstasy and Related Designer Drugs, 221–23. Dordrecht: Springer Netherlands, 2009. http://dx.doi.org/10.1007/978-90-481-2448-0_36.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Prepeliczay, Susanna. "Freizeitgebrauch von LSD und Psilocybin-Pilzen." In Handbuch Drogen in sozial- und kulturwissenschaftlicher Perspektive, 511–29. Wiesbaden: Springer Fachmedien Wiesbaden, 2018. http://dx.doi.org/10.1007/978-3-658-22138-6_35.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Waring, Duff R. "Opening Death’s Door: Psilocybin and Existential Suffering in Palliative Care." In Philosophy and Medicine, 235–62. Cham: Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-12692-5_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Nallaiyan, Boomika, Priyanka Jayam Rajendran, and Dhanasekaran Dharumadurai. "Mass Multiplication, Production Cost Analysis, and Marketing of Psilocybe Mushroom." In Food Microbiology Based Entrepreneurship, 57–76. Singapore: Springer Nature Singapore, 2023. http://dx.doi.org/10.1007/978-981-19-5041-4_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

"Psilocin." In Springer Reference Medizin, 2003. Berlin, Heidelberg: Springer Berlin Heidelberg, 2019. http://dx.doi.org/10.1007/978-3-662-48986-4_313134.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Stebelska, Katarzyna. "Assays for Detection of Fungal Hallucinogens Such as Psilocybin and Psilocin." In Neuropathology of Drug Addictions and Substance Misuse, 909–26. Elsevier, 2016. http://dx.doi.org/10.1016/b978-0-12-800212-4.00084-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Clarke, Zoe. "Psilocybin." In xPharm: The Comprehensive Pharmacology Reference, 1–4. Elsevier, 2007. http://dx.doi.org/10.1016/b978-008055232-3.62489-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Psilocyn"

1

Magiatis, P., E. Dadiotis, R. K. Antonopoulos, K. Ioannidis, V. Mitsis, E. Melliou, and Z. Gonou-Zagou. "Direct Quantitation of Psilocybin and Psilocin by One-Dimensional 1H and 31P qNMR in a revived Greek specimen of Psilocybe cyanescens." In GA – 70th Annual Meeting 2022. Georg Thieme Verlag KG, 2022. http://dx.doi.org/10.1055/s-0042-1759062.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Dooper, Marten. "Mode of action of psilocybin." In 35th ECNP Congress, edited by Christina Dalla. Baarn, the Netherlands: Medicom Medical Publishers, 2022. http://dx.doi.org/10.55788/9af70cfc.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Dooper, Marten. "Antidepressant properties of psilocybin might be related to changes in sleep." In 35th ECNP Congress, edited by Christina Dalla. Baarn, the Netherlands: Medicom Medical Publishers, 2022. http://dx.doi.org/10.55788/c6e5fc91.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Dooper, Marten. "Fast and sustained effect of 2 administrations of psilocybin on depression." In 35th ECNP Congress, edited by Christina Dalla. Baarn, the Netherlands: Medicom Medical Publishers, 2022. http://dx.doi.org/10.55788/0629715f.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Psilocyn"

1

Stoliker, Devon, and Adeel Razi. Taking psilocybin for science. Edited by Sara Phillips. Monash University, October 2022. http://dx.doi.org/10.54377/d188-22e2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Psilocyn' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography